- June 30, 2021
- Posted by: Stratford Team
- Category: Business
Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT™diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and released financial results for the fiscal year ended March 31, 2021.
- Received positive feedback from the first users of sugarBEAT® as part of the soft launch in the UK, leading to purchase order for 200,000 sensors and a rolling purchase order forecast for 2 million sensors over the next 2 years.
- Launch a digital healthcare subscription service in the U.S. under the brand name BEATdiabetes.life, targeted at over 25 million people with Type 2 diabetes and 88 million people with…